Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 7:11:1432865.
doi: 10.3389/fmed.2024.1432865. eCollection 2024.

Role and potential of 18F-fluorodeoxyglucose-positron emission tomography-computed tomography in large-vessel vasculitis: a comprehensive review

Affiliations
Review

Role and potential of 18F-fluorodeoxyglucose-positron emission tomography-computed tomography in large-vessel vasculitis: a comprehensive review

Javier Collada-Carrasco et al. Front Med (Lausanne). .

Abstract

Large-vessel vasculitis (LVV) is a group of diseases characterized by inflammation of the aorta and its main branches, which includes giant cell arteritis (GCA), polymyalgia rheumatica (PMR), and Takayasu's arteritis (TAK). These conditions pose significant diagnostic and management challenges due to their diverse clinical presentations and potential for serious complications. 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG-PET-CT) has emerged as a valuable imaging modality for the diagnosis and monitoring of LVV, offering insights into disease activity, extent, and response to treatment. 18F-FDG-PET-CT plays a crucial role in the diagnosis and management of LVV by allowing to visualize vessel involvement, assess disease activity, and guide treatment decisions. Studies have demonstrated the utility of 18F-FDG-PET-CT in distinguishing between LVV subtypes, evaluating disease distribution, and detecting extracranial involvement in patients with cranial GCA or PMR phenotypes. Additionally, 18F-FDG-PET-CT has shown promising utility in predicting clinical outcomes and assessing treatment response, based on the correlation between reductions in FDG uptake and improved disease control. Future research should focus on further refining PET-CT techniques, exploring their utility in monitoring treatment response, and investigating novel imaging modalities such as PET-MRI for enhanced diagnostic accuracy in LVV. Overall, 18F-FDG-PET-CT represents a valuable tool in the multidisciplinary management of LVV, facilitating timely diagnosis and personalized treatment strategies to improve patient outcomes.

Keywords: PET-CT; Takayasu’s arteritis; giant cell arteritis; large-vessel vasculitis; polymyalgia rheumatica.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
(A) Diagram representing the Leuven score for the assessment of PMR probability. A value on a 3-grade visual scale is assigned to each one of the 12 spots depicted, as follows: 0 means no uptake; 1 means less uptake than that of the liver, 2 means equal or more uptake than that of the liver. PMR is considered likely if the total score is equal or above 16 out of 24. (B) 18F-FDG-PET-CT of an 84-year old female with GCA at diagnosis. Symptoms were asthenia, weight loss, raised inflammatory markers and diffuse bone pain. Notice the intense metabolic activity in aorta and supra-aortic vessels (arrows). Visual score: 3. (C) 18F-FDG-PET-CT of the same patient. Notice the associated metabolic activity in shoulders, sternoclavicular joints, greater trochanters, ischial tuberosities and lumbar interspinous bursae (arrows). Leuven score: 18. Probable PMR was reported.

Similar articles

Cited by

References

    1. González-Gay MA, García-Porrúa C. Epidemiology of the vasculitides. Rheum Dis Clin N Am. (2001) 27:729–49. - PubMed
    1. De Smit E, Palmer A, Hewitt A. Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol. (2015) 42:119–25. 10.3899/jrheum.140318 - DOI - PubMed
    1. Fernández-Lozano D, Hernández-Rodríguez I, Narvaez J, Domínguez-Álvaro M, De Miguel E, Silva-Díaz M, et al. Incidence and clinical manifestations of giant cell arteritis in Spain: Results of the ARTESER register. RMD Open. (2024) 10:e003824. 10.1136/rmdopen-2023-003824 - DOI - PMC - PubMed
    1. Tomelleri A, van der Geest K, Khurshid M, Sebastian A, Coath F, Robbins D, et al. Disease stratification in GCA and PMR: State of the art and future perspectives. Nat Rev Rheumatol. (2023) 19:446–59. 10.1038/s41584-023-00976-8 - DOI - PubMed
    1. Salvarani C, Cantini F, Boiardi L, Hunder G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. (2002) 347:261–71. 10.1056/NEJMra011913 - DOI - PubMed

LinkOut - more resources